Iterum Therapeutics Plc (NASDAQ: ITRM) kicked off on Friday, down -6.12% from the previous trading day, before settling in for the closing price of $0.34. Over the past 52 weeks, ITRM has traded in a range of $0.26-$2.10.
During the last 5-year period, the sales growth of Healthcare Sector giant was 58.85%. While this was happening, its average annual earnings per share was recorded 25.84%. With a float of $52.37 million, this company’s outstanding shares have now reached $52.79 million.
Iterum Therapeutics Plc (ITRM) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Iterum Therapeutics Plc is 0.79%, while institutional ownership is 2.52%. The most recent insider transaction that took place on Nov 18 ’25, was worth 2,191. In this transaction Director of this company bought 6,000 shares at a rate of $0.37, taking the stock ownership to the 241,001 shares. Before that another transaction happened on Aug 08 ’25, when Company’s Director bought 15,000 for $0.72, making the entire transaction worth $10,854. This insider now owns 235,001 shares in total.
Iterum Therapeutics Plc (ITRM) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.12 earnings per share (EPS), higher than consensus estimate (set at -0.24) by 0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.77% during the next five years compared to 58.85% growth over the previous five years of trading.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
Take a look at Iterum Therapeutics Plc’s (ITRM) current performance indicators. Last quarter, stock had a quick ratio of 1.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 42.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.31 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
As of the previous 9 days, the stock’s Stochastic %D was 48.08%.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 8.42%, which indicates a significant decrease from 23.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0373 in the past 14 days, which was lower than the 0.0480 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4793, while its 200-day Moving Average is $0.8094. However, in the short run, Iterum Therapeutics Plc’s stock first resistance to watch stands at $0.3355. Second resistance stands at $0.3566. The third major resistance level sits at $0.3718. If the price goes on to break the first support level at $0.2992, it is likely to go to the next support level at $0.2840. Now, if the price goes above the second support level, the third support stands at $0.2629.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
The company with the Market Capitalisation of 16.60 million has total of 52,788K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -24,770 K annual income. Company’s last quarter sales were recorded 390 K and last quarter income was -8,980 K.
